| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018072607 | 2018-01-15 | ||
| PCT/CN2019/071711WO2019137548A1 (en) | 2018-01-15 | 2019-01-15 | Antibodies and variants thereof against tigit |
| Publication Number | Publication Date |
|---|---|
| SG11202005595YAtrue SG11202005595YA (en) | 2020-07-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005595YASG11202005595YA (en) | 2018-01-15 | 2019-01-15 | Antibodies and variants thereof against tigit |
| Country | Link |
|---|---|
| US (1) | US11708410B2 (en) |
| EP (1) | EP3740508A4 (en) |
| JP (1) | JP7316284B2 (en) |
| KR (1) | KR20200109313A (en) |
| CN (1) | CN111601826B (en) |
| AU (1) | AU2019207296A1 (en) |
| CA (1) | CA3088332A1 (en) |
| IL (1) | IL275737A (en) |
| SG (1) | SG11202005595YA (en) |
| TW (1) | TW201932489A (en) |
| WO (1) | WO2019137548A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3618863T3 (en) | 2017-05-01 | 2023-08-21 | Agenus Inc | ANTI-TIGIT ANTIBODIES AND METHODS OF USING THEREOF |
| KR20210108978A (en) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | Bifunctional Anti-PD-1/IL-7 Molecules |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN111995681B (en)* | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | anti-TIGIT antibody, preparation method and application thereof |
| KR20230024368A (en) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
| CN114539405B (en)* | 2020-11-23 | 2024-02-23 | 广东菲鹏制药股份有限公司 | anti-TIGIT antibodies or antigen-binding fragments thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (en) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties. |
| AR125753A1 (en) | 2021-05-04 | 2023-08-09 | Agenus Inc | ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THESE |
| CN115466327B (en)* | 2021-06-10 | 2025-07-08 | 北京天广实生物技术股份有限公司 | Antibodies that bind to TIGIT and uses thereof |
| JP2024527049A (en) | 2021-07-28 | 2024-07-19 | ジェネンテック， インコーポレイテッド | Methods and Compositions for Treating Cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN118591557A (en)* | 2022-01-24 | 2024-09-03 | 原启生物科技(上海)有限责任公司 | Antigen binding proteins targeting TIGIT and uses thereof |
| KR20250022049A (en) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (en) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Multifunctional molecules against CD28 |
| WO2024041639A1 (en)* | 2022-08-26 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting tigit and uses thereof |
| CN116444653B (en)* | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | Preparation and application of blocking African swine fever virus monoclonal antibody hybridoma cell strain |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025002151A1 (en)* | 2023-06-27 | 2025-01-02 | 正大天晴药业集团股份有限公司 | Anti-tigit antibodies and use thereof |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073644B (en) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof |
| CA2953245A1 (en)* | 2014-07-16 | 2016-01-21 | Genentech, Inc. | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| MD4733C1 (en)* | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
| CA3138083A1 (en)* | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| KR102644115B1 (en)* | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies to tigit |
| TWI715587B (en)* | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
| PE20181292A1 (en)* | 2015-08-20 | 2018-08-07 | Abbvie Stemcentrx Llc | ANTI-DLL3-DRUG ANTIBODY CONJUGATES AND METHODS OF USE |
| TWI811892B (en)* | 2015-09-25 | 2023-08-11 | 美商建南德克公司 | Anti-tigit antibodies and methods of use |
| DK3356413T3 (en)* | 2015-10-01 | 2022-04-11 | Potenza Therapeutics Inc | ANTI-TIGIT ANTIGEN BINDING PROTEINS AND METHODS FOR USING IT |
| EP3565839A4 (en)* | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
| Publication number | Publication date |
|---|---|
| KR20200109313A (en) | 2020-09-22 |
| CN111601826A (en) | 2020-08-28 |
| AU2019207296A1 (en) | 2020-07-16 |
| EP3740508A1 (en) | 2020-11-25 |
| IL275737A (en) | 2020-08-31 |
| CA3088332A1 (en) | 2019-07-18 |
| EP3740508A4 (en) | 2022-03-23 |
| JP7316284B2 (en) | 2023-07-27 |
| CN111601826B (en) | 2023-12-15 |
| JP2021510710A (en) | 2021-04-30 |
| TW201932489A (en) | 2019-08-16 |
| US20210095028A1 (en) | 2021-04-01 |
| US11708410B2 (en) | 2023-07-25 |
| WO2019137548A1 (en) | 2019-07-18 |
| Publication | Publication Date | Title |
|---|---|---|
| IL275737A (en) | Antibodies and variants thereof against tigit | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL289585A (en) | Dll3-targeting antibodies and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL289656A (en) | Anti-tigit antibodies and application thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and uses thereof |